In vitro target validation and in vivo efficacy of p38 MAP kinase inhibition in established chronic collagen-induced arthritis model a pre-clinical study
From the day of onset of arthritis, mice were treated with GW856553X (0.8mg/kg, 4mg/kg or 20mg/kg Fig. 2. GW856553X reduces chronic CIA.
daily), vehicle alone or left untreated (n=5-7 per group). (period, ANOVrepresented A and versusdata vehicle-treated mice: are expressed as mean ± SEM. Statistical a) Clinical score was assessed over a 4 week analysis was carried out using a 2-way versus vehicle-treated mice: as box-and-whiskers ***p<0.001.
plots. ***pStatistical <0.001. (banalysis ) Area-under-curve analysis of clinical score data, was carried out using a 1-way ANOVA were Biochemical, decalci ed (Rapid-Cal , BBC (London, embedded guidelines UK) in accordance with the tions in Dallas, TX, USA) and Ethics and of 5μm paraf n thickness wax. were Serial dewaxed sec-man Committee of the Riverside Research eosin. The stained sections were scored stained with haematoxylin and (HUVEC) umbilical microscopically for changes to joint ar-of were vein (RREC 2948). Hu-isolated endothelial by cells chitecture by an observer blinded to the ml umbilical cord veins in digestion study Mannheim, collagenase A 0.025mg/ankle, groups. Arthritic changes in were maintained in RPMI 1640 (Cam-Germany) (Roche (3, Diagnostics, 16). Cells interphalangeal, metatarsophalangeal, the brex, geal joints were individually graded as and distal interphalan-proximal foetal calf serum (FCS; Biowest, Nuail-Berkshire, UK) containing 10% follows: 0=normal, 1=moderate (pannus lé, France), 10% new born calf serum formation and erosions (Gibco, cartilage-pannus (CP vere (more extended bone and cartilage formation), limited and to 2=se-the and Pharmaceuticals, Paisley, UK), 5U/ml heparin erosions, with loss of joint architecture).supplement 15μg/ml endothelial Wrexham, UK), UK). To (Sigma Aldrich, cell growth Poole, Endothelial cell studies
modi ed assay for mitochondrial activ-measure HUVEC viability, a Human umbilical cords were collected ity from Chelsea and Westminster Hospital GW856553X (1-100nM) for 24 hours. was used. Wells were treated with Following treatment as above, 0.5mg/
179
ml diphenyltetrazolium; MTT (3-[4,5-dimethyl-2-yl]-2,5-Poole, UK) was added to the cells over-Sigma Aldrich, night. Cells were lysed using 10% SDS containing 0.001M HCl, and absorption was measured after 24 hours at 620nm.In GW856553X on angiogenesis, a com-order to analyse the effect of mercially was used (AngioKit; TCS Cell Works, available angiogenesis kit Buckingham, on day 0 with VEGF, in the absence or UK). Wells were treated presence of vehicle GW856553X of increasing or 0.01% concentrations replenished control. cording to manufacturer’s instructions. after Culture 4, 7 and medium DMSO as 9 days was ac-On and day perature the 11, cells the were medium xed was at room aspirated tem-pression in ice-cold 70% ethanol. Ex-staining with mouse anti-human CD31 of CD31 was visualised by antibody (TCS Cell Works, UK, Buck-ingham, followed by goat anti-mouse IgG alka-UK) for 60 minutes at 37°C, line phosphatase conjugate for 10 min-utes at room temperature. CD31 ELISA substrate p-nitrophenol was and phosphate prepared by in Tris dissolving turer’s instructions. The plate was read was added according to manufac-buffer at ble 405nm. Subsequently, an bromo-4-chloro-3-indolyl substrate prepared from BCIP insolu-NBT (nitro blue tetrazolium; TCS Cell phosphate)/(5-Works, UK) was added. Once the sub-strate per tubules developed a dark colour (5-15 well was and ltered, incubated 0.5ml at was 37°C added until minutes). Wells were then washed three times before with BH2 microscope (Olympus Optical, Ja-microscopic distilled Hcapture 2O and air using dried a pan) linked to a KY-F55BE video cam-era (Victor Company, Japan).
To assess migration, 2x105RPMI 1% FCS were seeded onto gela- HUVEC in tin-coated inserts polycarbonate ley, Oxon, UK) and allowed to migrate 8μm (Becton Dickinson, cell culture Cow-for DMSO as vehicle control was added to 6 hours. GW856553X or 0.01% both migration upper were period, and lower wells. After the the membrane, and the insert was trans-removed from non-migrating the upper side cells of ferred to a clean well containing 300μ

l
p38 inhibition and not MK2 inhibition enhances ...efficacy in in vitro and in vivo inflammatory ... Novel inhibitor of p38 MAP kinase as an anti...
(2013) In Vitro and In Vivo Experimental Models...Efficacy of Antineoplastic Drugs on Urinary Bladder...inhibition are the oldest and most commonly used ...
The potent anti-leukemia efficacy of Icaritin in murine model demonstrated ... Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a...
of 4T1 breast cancer in vitro and in vivo. ...In vivo growth-inhibition of Sarcoma 180 by ...Chemopreventive efficacy of curcumin and piperine ...
namely stimulation of osteoblastic cell proliferation and inhibition of ...In summary, the present study clearly demonstrates the in vivo efficacy of ...
Experimental models of elevated Pgc in vivo ...In vitro mechanical stimulation therefore represents ...of p38 MAP kinase and subsequent inhibition by ...
Target validation Seattle/Chicago: Structure ...(in vitro systems) Biochemical (kinase, protease,...Inhibition Slide 20 deCODE Capabilities: In Vivo ...
In vitro models (enzyme inhibition, receptor ...and in silico) Bottleneck: Target validation, “... www.kubinyi.de MAP Kinase Pathways Kinases www....
[1] Target: p38 MAPK in vitro: In SHR-SPs receiving a salt-fat diet...Analgesic efficacy and safety of the novel p38 MAP kinase inhibitor, ...
Efficacy of a Tyrosine... 暂无评价 9页 免费 ...in vitro screening for tyrosine kinase inhibitors ...Also, there is substantial in vivo inhibition of...
热门文档